本季度信息
截至2025年12月31日止六个月，国药科技股份有限公司实现营收26,769,000港元，上年同期为18,898,000港元，约同比增长42%。毛利为5,319,000港元，对应毛利率约20%，上年同期毛利率约34%。经营现金流有所改善，报告期内经营活动所得现金净额为1,988,000港元，而上年同期则为-781,000港元。成本方面，销售及分销开支为1,072,000港元，同比下降约65%，管理及经营开支则为5,794,000港元，同比上升约6%。
业务分项
期内供应链服务收入为26,769,000港元，上年同期为18,898,000港元，增幅主要来自相关货品交易量提升。“互联网+”解决方案服务并未产生收入。个人防护装备业务继续暂停投入。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.